Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
Hodgkin's Lymphoma | Lymphoid Leukemia | Non-Hodgkin's Lymphoma
Phase Expanded Access
What is the purpose of this trial?
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.
- Trial withNovartis Pharmaceuticals
- Start Date08/20/2019
- End Date06/30/2022
- Last Updated07/15/2021
- Study HIC#2000025634